The results showed that targeting wild-type IDH1 inhibition shifted leukemia cell metabolism toward oxidative phosphorylation from glycolysis, enhanced ROS, and deregulated membrane potential, leading to cell death. The gene discussed is IDH1; the disease is leukemia.